Ramona Vladea, PhD

AbbVie, Inc.

Poster(s):

• A0329 - Benefit–Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis
  Sunday, October 23, 2022

  5:00 PM – 7:00 PM ET